Akèy › Kansè Poumon ki pa ti selil › Washington › Spokane
Etid klinik pou Kansè Poumon ki pa ti selil nan Spokane, WA
12 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Spokane (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Ap rekriteFaz 3
- Local Institution - 0384, Spokane
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Summit Cancer Centers, Spokane
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Medical Oncology Associates - Spokane /ID# 277172, Spokane
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, Spokane
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Summit Cancer Treatment Center, Spokane
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Providence Sacred Heart Medical Center, Spokane
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Ap rekriteFaz 1
- Summit Cancer Center, Spokane
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Ap rekriteFaz 3
- Medical Oncology Associates - Summit Cancer Centers, Spokane
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- Medical Oncology Associates, Spokane
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA07-0, Spokane
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 105, Spokane
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Spokane
- Kansè nan tete8 etid
- Kansè ovè8 etid
- Kansè kolorektal8 etid
- Maladi Parkinson7 etid
- Kansè pwostat6 etid
- Lukemi lenfositè kwonik6 etid
- Karsinòm selil skuamèz tèt ak kou6 etid
- Kansè (tout kalite)6 etid
- Kansè tete negatif triple5 etid
- Melanom5 etid
- Degeneresans makile5 etid
- Atrofi Jeyografik5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.